La cadena de opciones muestra datos clave de las opciones de acciones de Veracyte a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Veracyte..

Veracyte (NASDAQ:VCYT) Bolsa, Cadena de Opciones

Veracyte

Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.

Veracyte Inc

Scotiabank analyst Sung Ji Nam maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Sector Outperform and raises the price target from $40 to $44.

News

Price Target

Analyst Ratings

VCYT

Scotiabank Maintains Sector Outperform on Veracyte, Raises Price Target to $44

Goldman Sachs analyst Matthew Sykes maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy and raises the price target from $34 to $38.

Goldman Sachs Maintains Buy on Veracyte, Raises Price Target to $38

WIIM

Veracyte shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance. Needham and UBS maintained Buy ratings and raised their respective price targets on the stock.

UBS analyst Lu Li maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy and raises the price target from $43 to $46.

UBS Maintains Buy on Veracyte, Raises Price Target to $46

Needham analyst Mike Matson maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy and raises the price target from $37 to $44.

Needham Maintains Buy on Veracyte, Raises Price Target to $44

Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.03 by 1000 percent. The company reported quarterly sales of $115.860 million which beat the analyst consensus estimate of $109.812 million by 5.51 percent. This is a 28.58 percent increase over sales of $90.108 million the same period last year.

Earnings

Earnings Beats

Veracyte Q3 2024 Adj. EPS $0.33 Beats $0.03 Estimate, Sales $115.860M Beat $109.812M Estimate

Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) raises FY2024 sales outlook from $432.00 million-438.00 million to $442.00 million-445.00 million.

Guidance

Veracyte Raises FY2024 Sales Guidance from $432.00M-438.00M to $442.00M-445.00M  VS Est. 436.14M

Leerink Partners analyst Puneet Souda maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Outperform and raises the price target from $35 to $40.

Leerink Partners Maintains Outperform on Veracyte, Raises Price Target to $40

UBS analyst Lu Li initiates coverage on Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy rating and announces Price Target of $43.

Initiation

UBS Initiates Coverage On Veracyte with Buy Rating, Announces Price Target of $43

Across the recent three months, 4 analysts have shared their insights on Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $33.5, a high estimate of $40.00, and a low estimate of $26.00. Witnessing a positive shift, the current average has risen by 27.23% from the previous average price target of $26.33.
<img src="https://www.benzinga.com/files/images/story/2024/1728576028_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Veracyte is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$37.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$26.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$31.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Veracyte. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Veracyte compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Veracyte's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Veracyte's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VCYT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Veracyte analyst ratings.</a>
<h2>About Veracyte</h2>
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.
<h3>Breaking Down Veracyte's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Veracyte showcased positive performance, achieving a revenue growth rate of 26.69% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Veracyte's net margin is impressive, surpassing industry averages. With a net margin of 5.01%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Veracyte's ROE excels beyond industry benchmarks, reaching 0.51%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Veracyte's ROA excels beyond industry benchmarks, reaching 0.47%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.02.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Veracyte: 4 Analysts Share Their Views

Guggenheim analyst Subbu Nambi initiates coverage on Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy rating and announces Price Target of $40.

Guggenheim Initiates Coverage On Veracyte with Buy Rating, Announces Price Target of $40

Findings are from the prospective, multicenter VANDAAM trial
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.veracyte.com%2F&amp;esheet=54130421&amp;newsitemid=20241002846726&amp;lan=en-US&amp;anchor=Veracyte%2C+Inc&amp;index=1&amp;md5=34ebf73283d8ccb09db73586947cabed">Veracyte, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), a leading cancer diagnostics company, announced that new data from the multicenter, prospective <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT02723734&amp;esheet=54130421&amp;newsitemid=20241002846726&amp;lan=en-US&amp;anchor=VANDAAM+trial&amp;index=2&amp;md5=df7962e3c767658f465ed8d0a0feb6e7">VANDAAM trial</a> show that the Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer among African American men with early-stage disease. The findings confirm that the market-leading genomic test offers clinicians an improvement over clinical factors alone in guiding prostate cancer treatment decisions for African American men, a population that is disproportionately impacted by the disease. The new data were shared today in an oral presentation at ASTRO 2024, the annual meeting of the American Society for Radiation Oncology, in Washington, D.C.
African American men are more than 70% as likely to be diagnosed with prostate cancer and more than twice as likely to die of the disease, compared to white men, according to the American Cancer Society.1 Despite this, few prospective studies have specifically sought to examine the disease at a genomic level in this population.

Biotech

General

Veracyte Presents New Data Findings Are From The Prospective, Multicenter VANDAAM Trial, Show That Its Decipher Prostate Test Predicts Aggressive Prostate Cancer In African American Men At ASTRO 2024

<ul>
<li>Findings are from ancillary study of phase 3 STAMPEDE trial</li>
<li>Data support company&#39;s plan to expand Decipher Prostate test to patients with metastatic disease</li>
</ul>

Reported Sunday, Data Presented At ESMO 2024 Reveals Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit In Metastatic Prostate Cancer Patients

Insulet Corp.&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/podd#NASDAQ">PODD</a>) recent FDA approval of Omnipod 5 for type 2 diabetes patients is set to expand the product&#39;s market potential. The planned launch of Omnipod 5 with Abbott&#39;s Freestyle Libre 2 Plus sensor is likely to drive further growth in the U.S. markets. Robust financial strength also bodes well for the stock. However, the rising economic uncertainty and competitive pressures remain concerns for the company.
In the past year, this Zacks Rank #3 (Hold) stock has rallied 7.6% compared with the 15.5% growth of the industry and the 24.9% rise of the S&amp;P 500 composite.
The developer, manufacturer and distributor of insulin delivery systems has a market capitalization of $14.22 billion. PODD&#39;s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 67.5%.
<h2>Catalysts for PODD Stock</h2>
Omnipod 5, a New Focus: Insulet&#39;s game-changing Omnipod 5 stands out as the only FDA-cleared, fully disposable pod-based AID system. The product attributes, such as on-body wearable, simplicity, ease of use and broad accessibility, are the key drivers of its rapid adoption and are successfully driving market growth. The second quarter saw nearly 85% of the new starts coming from people previously using MDI, Insulet&#39;s target market, while competitive conversions also remained very strong. The company is driving growth rates above 20% in international revenues, underscoring the strong potential for Omnipod 5&#39;s continued expansion. On a promising note, Omnipod 5 recently received the FDA&#39;s usage clearance by people with type 2 diabetes (aged 18 years and above) in the United States.
Expanding Access and Awareness of Omnipod: One of Insulet&#39;s key strategic imperatives is to increase the availability and visibility of Omnipod products. In the second quarter of 2024, Omnipod 5 integrated with Dexcom&#39;s G6 CGM drove 27% growth in U.S. Omnipod revenues. The company began the full market release of Omnipod 5 with G7, available exclusively through several specialty pharmacies.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/98/76485.jpg?v=914640466" /> 
Image Source: Zacks Investment Research
On the latest earnings call, Insulet hinted at launching Omnipod 5 with Abbott&#39;s Freestyle Libre 2 Plus sensor in the United States by the end of this year. The combination had a limited market release in the United Kingdom and the Netherlands during the first quarter. Further, Omnipod DASH is driving strong new customer starts in the U.S. type 2 diabetes market.
Strong Solvency but Leveraged Balance Sheet: Insulet exited the second quarter of 2024 with cash and cash equivalents of $821 million and current debt of $38 million. This robust financial stability appears highly promising during the prolonged period of macroeconomic issues.&nbsp; Long-term debt of $1.36 billion remained marginally in line with the 2024 first-quarter figure.
<h2>Factors Weighing on Insulet Stock</h2>
Economic Uncertainty Hampers Growth: The continuing worldwide macroeconomic and geopolitical uncertainty may reduce the demand for Insulet&#39;s products, intensify competition, exert pressure on prices, dent supply and lengthen the sales cycle. The company continues to experience challenges stemming from the global supply chain disruption. Its reliance on third-party suppliers in China could face potential risks from political or financial instability and labor unrest, among others.
Tough Competitive Pressure:&nbsp;Insulet operates in a highly competitive environment dominated by firms ranging from large multinational corporations with significant resources to start-ups. It also competes with companies offering products and supplies for MDI therapy, which is the most prevalent method of insulin delivery. Regulatory conditions limit the company&#39;s ability to switch to strategies like price increases and other drivers of cost increases. With competitors potentially developing effective patch pumps or breakthrough diabetes treatments that do not require the delivery of insulin, sales of Omnipod may be negatively affected.
<h2>PODD Estimate Trend</h2>
The Zacks Consensus Estimate for Insulet&#39;s 2024 earnings per share has decreased 1.6% to $3.04 in the past 30 days.
The Zacks Consensus Estimate for the company&#39;s 2024 revenues is pegged at $2.01 billion. This suggests an 18.3% rise from the year-ago reported number.
<h2>Top MedTech Stocks</h2>
Some better-ranked stocks in the broader medical space are TransMedix Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>), Veracyte (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vcyt#NASDAQ">VCYT</a>) and Boston Scientific (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>). While TransMedix Group and Veracyte currently sport a Zacks Rank #1 (Strong Buy), Boston Scientific carries a Zacks Rank #2 (Buy).
TransMedix Group&#39;s earnings are expected to surge 255.8% in 2024. Its shares have soared 130.6% compared with the industry&#39;s 11% rise in the past year.
TMDX&#39;s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 287.5%.
Veracyte has an estimated earnings growth rate of 112.8% compared with the industry&#39;s 12.4%. Shares of the company have soared 13.4% compared with the industry&#39;s 10.9% rise over the past year.
VCYT&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 328.4%.
Boston Scientific has an estimated earnings growth rate of 17.1% compared with the industry&#39;s 14.9%. Shares of the company have rallied 51.3% compared with the industry&#39;s 15.5% rise over the past year.
BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.2%.
<a href="https://www.zacks.com/stock/news/2331170/should-you-continue-to-retain-podd-stock-in-your-portfolio-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2331170">To read this article on Zacks.com click here.</a>

Large Cap

Mid Cap

Markets

Trading Ideas

PODD

TMDX

Should You Continue to Retain PODD Stock in Your Portfolio Now?

Needham analyst Mike Matson maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy and raises the price target from $31 to $37.

Needham Maintains Buy on Veracyte, Raises Price Target to $37

Alcon, Inc.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/alc#NYSE">ALC</a>) delivered core earnings per share of 74 cents in the second quarter of 2024, up 7.2% from the year-ago quarter&#39;s figure (up 15% at the constant exchange rate or CER). The figure came in line with the Zacks Consensus Estimate.
Alcon reports &lsquo;core&#39; results based on non-IFRS (International Financial Reporting Standards) measures. In the second quarter, the company&#39;s diluted EPS was 45 cents, up 32.4% year over year.
<h3>Revenues in Detail</h3>
Alcon&#39;s net sales to third parties in the second quarter were $2.48 billion, which missed the Zacks Consensus Estimate by 1.4%. However, the top line increased by 3.3% from the year-ago quarter&#39;s levels (up 6% at CER).
<h3>Quarter in Detail</h3>
Alcon reports operations through two segments &mdash; Surgical (comprising Implantables, Consumables and Equipment/Other) and Vision Care (comprising Contact Lenses and Ocular Health).
Surgical
In the second quarter of 2024, Surgical sales amounted to $1.42 billion, up 3% year over year and 6% at CER. Our model projected the segment&#39;s growth to be 3.5% versus the prior year.
Within this, net sales in Implantables increased 6%, led by the demand for advanced technology intraocular lenses in international markets. Our model projected 3.1% year-over-year growth.
Consumables increased 3%, mainly driven by cataract and vitreoretinal consumables, particularly in international markets, and price increases. Our model&#39;s projection was an increase of 4.9%.
<div class="chart_embed">
<h3>Alcon Price, Consensus and EPS Surprise</h3>
<img alt="Alcon Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/dc/1724230877.png" style="height:265px; width:576px" title="" />
Alcon price-consensus-eps-surprise-chart | Alcon Quote
</div>
Equipment/Other was down 3% from the prior-year quarter&#39;s levels. Our model forecast stood at 0.1% growth.
Vision Care
The segment reported total sales of $1.11 billion, up 7% year over year on a reported basis and 10% at CER. Our model&#39;s projection was 6.7% growth.
Net sales of Contact Lenses increased 9% year over year, driven by product innovation, including toric multifocal modalities and price increases. This surpassed our model&#39;s projected growth of 8% year over year.
Ocular Health sales increased 5% year over year, primarily driven by the portfolio of eye drops, including continued strength from the Systane family of artificial tears. Our model forecast was 4.9%.
<h3>Margins</h3>
The cost of net sales in the second quarter was $1.12 billion, up 5.9% year over year. The core gross profit rose 0.8% to $1.37 billion in the reported quarter. Meanwhile, the core gross margin contracted 123 basis points (bps) to 55.1% in the second quarter of 2024.
SG&amp;A expenses increased 0.6% year over year, while R&amp;D expenses rose 1.4% year over year. The core operating margin fell 26 bps in the second quarter to 12.7%.
<h3>Financial Position</h3>
Alcon exited the second quarter of 2024 with cash and cash equivalents of $1.37 billion compared with $1.14 billion at the end of the first quarter.
The cumulative net cash flow from operating activities at the end of the second quarter was $871 million compared with $410 million in the year-ago period. Free cash flow totaled $667 million at the end of the second quarter of 2024 compared with $189 million in the comparable 2023 months.
<h3>2024 Outlook</h3>
Alcon reiterated its financial outlook for 2024.
The company anticipates 2024 net sales in the range of $9.90-$10.10 billion (unchanged), indicating growth of 7%-9% at CER from 2023. The Zacks Consensus Estimate for ALC&#39;s revenues is pegged at $9.94 billion.
Core EPS for the full year is expected in the range of $3.00-$3.10 (same as earlier). This suggests growth of 15%-18%% at CER from the 2023 levels. The Zacks Consensus Estimate for Alcon&#39;s 2024 earnings is currently pegged at $3.05 per share.
<h3>Our Take</h3>
Alcon closed the second quarter of 2024 with in-line earnings, while revenues missed estimates. On a positive note, the top line improved on a year-over-year basis. The performance was driven by robust demand for the company&#39;s innovative products, balanced geographic footprint and strong execution by the team. Growth in the Vision Care segment underscores the strength of contact lenses.
In June 2024, Alcon&#39;s innovations from the highly anticipated UNITY portfolio, Vitreoretinal Cataract System and Cataract System, secured the FDA&#39;s 510(k) clearance. In the second half of the year, Alcon is preparing for product launches that are set to drive its next phase of growth in 2025 and beyond.
Meanwhile, the contraction of both margins in the quarter is discouraging.
<h3>Zacks Rank and Other Key Picks</h3>
Alcon currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Intuitive Surgical, DaVita Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>) and Veracyte (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vcyt#NASDAQ">VCYT</a>).
Intuitive Surgicalreported a third-quarter 2024 adjusted EPS of $1.78, which beat the Zacks Consensus Estimate by 16.3%. Revenues of $2.01 billion topped the consensus estimate by 2%. ISRG currently sports a Zacks Rank #1 (Strong Buy).
Intuitive Surgical has an estimated long-term earnings growth rate of 16.8% in 2024 compared with the industry&#39;s 11.8%. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, the average being 8.97%.
DaVita, sporting a Zacks Rank #1, reported second-quarter 2024 adjusted earnings of $2.59, which surpassed the Zacks Consensus Estimate by 4.9%. Revenues of $3.19 billion topped the Zacks Consensus Estimate by 0.7%.&nbsp;
DVA has an estimated long-term earnings growth rate of 17.5% compared with the industry&#39;s 12.4%. The company surpassed earnings estimates in each of the trailing four quarters, the average being 24.2%.
Veracyte, sporting a Zacks Rank #1, reported second-quarter diluted earnings of 30 cents per share compared with the Zacks Consensus Estimate of a loss of 3 cents. Revenues of $114.4 million exceeded the Zacks Consensus Estimate by 14%.
VCYT has an estimated 2024 earnings growth rate of 112.8% compared with the industry&#39;s 11.8%. The company surpassed earnings estimates in each of the trailing four quarters, the average being 328.4%.
<a href="https://www.zacks.com/stock/news/2324779/alcon-alc-q2-earnings-meet-estimates-revenues-increase-y-y?cid=CS-BENZ-FT-analyst_blog|earnings_article-2324779">To read this article on Zacks.com click here.</a>

Alcon Q2 Earnings Meet Estimates, Revenues Increase Y/Y

After reaching an important support level, Veracyte, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vcyt#NASDAQ">VCYT</a>) could be a good stock pick from a technical perspective. VCYT recently experienced a &quot;golden cross&quot; event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
There&#39;s a reason traders love a golden cross -- it&#39;s a technical chart pattern that can indicate a bullish breakout is on the horizon. This kind of crossover is formed when a stock&#39;s short-term moving average breaks above a longer-term moving average. Typically, a golden cross involves the 50-day and the 200-day moving averages, since bigger time periods tend to form stronger breakouts.
There are three stages to a golden cross. First, there must be a downtrend in a stock&#39;s price that eventually bottoms out. Then, the stock&#39;s shorter moving average crosses over its longer moving average, triggering a positive trend reversal. The third stage is when a stock continues the upward momentum to higher prices.
A golden cross is the opposite of a death cross, another technical event that indicates bearish price movement may be on the horizon.
Shares of VCYT have been moving higher over the past four weeks, up 41.7%. Plus, the company is currently a #1 (Strong Buy) on the Zacks Rank, suggesting that VCYT could be poised for a breakout.
The bullish case solidifies once investors consider VCYT&#39;s positive earnings outlook. For the current quarter, no earnings estimate has been cut compared to 3 revisions higher in the past 60 days. The Zacks Consensus Estimate has increased too.
<img alt="Moving Average Chart for VCYT" class="chart" src="https://staticx-tuner.zacks.com/images/articles/charts/yseop/549/VCYT_SMA50_200.jpeg" style="height:auto; width:100%" title="" />
Given this move in earnings estimates and the positive technical factor, investors may want to keep their eye on VCYT for more gains in the near future.
<a href="https://www.zacks.com/stock/news/2323785/veracyte-vcyt-just-flashed-golden-cross-signal-do-you-buy?cid=CS-BENZ-FT-tale_of_the_tape|golden_crossover-2323785">To read this article on Zacks.com click here.</a>

Technicals

Veracyte Just Flashed Golden Cross Signal: Do You Buy?

Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Underweight and raises the price target from $21 to $26.

Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $26

These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) shares jumped 113.82% after the company <a href="https://www.benzinga.com//node/40204727" target="_blank" rel="noreferrer noopener">reported second-quarter revenue results</a>. Multiple analysts either upgraded or <a href="https://www.benzinga.com//node/40221474" target="_blank" rel="noreferrer noopener">raised price targets on the stock</a>.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) stock jumped 73.65% after the company <a href="https://www.benzinga.com//node/40227720" target="_blank" rel="noreferrer noopener">reported strong second-quarter results</a>. Many analysts <a href="https://www.benzinga.com//node/40229270" target="_blank" rel="noreferrer noopener">upped the price target on the stock</a>.</li>
<li>ADMA Biologics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) stock gained 52.58% in the last week on reporting better-than-expected Q2 financial results.</li>
<li>Sweetgreen Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) stock gained 47.35% after the company reported <a href="https://www.benzinga.com//node/40284819" target="_blank" rel="noreferrer noopener">better-than-expected second-quarter financial results</a> and issued a strong FY24 revenue outlook. Several analysts<a href="https://www.benzinga.com/quote/SG/analyst-ratings" target="_blank" rel="noreferrer noopener"> raised the company&#8217;s price target</a>.</li>
<li>Veracyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) shares escalated 46.57% after the company reported <a href="https://www.benzinga.com//node/40229725" target="_blank" rel="noreferrer noopener">better-than-expected second-quarter financial results</a>.</li>
<li>Clear Secure, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>) stock increased 38.83% after the company reported second-quarter financial results and issued Q3 <a href="https://www.benzinga.com//node/40181525" target="_blank" rel="noreferrer noopener">revenue guidance above estimates</a>.</li>
<li>Core Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) shares upped 38.37% after the company announced that CoreWeave exercised an additional <a href="https://www.benzinga.com//node/40194866" target="_blank" rel="noreferrer noopener">contract option</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/08/40303623/warner-bros-airbnb-and-monster-beverage-are-among-top-10-large-cap-losers-last-week-aug-4-aug-10-a" target="_blank" rel="noreferrer noopener">Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers  Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/24/08/40303526/shopify-palantir-and-uber-are-among-top-10-large-cap-gainers-last-week-aug-4-aug-10-are-the-others-i" target="_blank" rel="noreferrer noopener">Shopify, Palantir And Uber Are Among Top 10 Large Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?</a></li>
</ul>
Photo courtesy of Lumen

Movers

ADMA

Core Scientific, Inc. - Class A Common Stock

CORZ

LUMN

UPST

Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?

On Tuesday, Veracyte, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) reported second-quarter sales of $114.43 million, up 27% year over year, beating the consensus of $100.3 million.
Testing revenue was $107.0 million, an increase of 31%, driven by the strong performance of our Decipher Prostate and Afirma tests.
Total test volume grew to 39,023, an increase of 23% compared to the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40201508/veracyte-announces-second-quarter-2024-financial-results" rel="noreferrer noopener">second quarter of 2023</a>.
During the quarter, the company achieved a record Decipher Prostate test volume of close to 19,900 tests, driven by recently updated NCCN prostate cancer guidelines, in which the Decipher Prostate test received the highest-level rating among gene expression tests.
The company delivered a record Afirma test volume of approximately 15,700 and received Medicare coverage for Afirma testing of patients with thyroid nodules classified as &#8220;Bethesda V,&#8221; giving more patients annually access to the test.
The diagnostics company reported adjusted EPS of $0.30, up from $0.12 a year ago, beating the consensus loss of $(0.02).
Guidance: Veracyte raised its full-year 2024 revenue guidance to $432 million-$438 million, up from $402 million-$410 million and above the consensus of $406.27 million.
The guidance represents year-over-year growth of 20%-21% and testing revenue growth of approximately 25%, compared to prior guidance of 11%-14% and <a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/b38681284/veracyte-announces-first-quarter-2024-financial-results" rel="noreferrer noopener">testing growth of 15%-18%</a>.
The company now expects cash, cash equivalents, and short-term investments at the end of the year to be $260 million to $270 million compared to prior guidance of $236 million to $240 million.
William Blair writes, &#8220;This was an all-around very good quarter for Veracyte, and there simply is not all that much to pick at.
&#8220;Management extended its long string of quarterly beats, and the increased guidance for revenue and cash generation should highlight the company as a profitable grower in a group where few names like this exist,&#8221; the analyst added.
The analyst maintains an Outperform rating, noting the numbers going higher, and with confidence in the team&#8217;s ability to execute on several growth drivers over the near and long term.
Needham maintains Veracyte with a Buy and raises the <a target="_blank" href="https://www.benzinga.com/quote/VCYT/analyst-ratings" rel="noreferrer noopener">price target from $27 to $31</a>.
Price Action: VCYT stock is up 24.60% at $27.19 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40226161/vaccine-maker-emergent-biosolutions-expects-deeper-losses-in-2024-stock-sinks" target="_blank" rel="noreferrer noopener">Vaccine Maker Emergent BioSolutions Expects Deeper Losses In 2024, Stock Sinks</a>.</li>
</ul>

Analyst Color

Health Care

Reiteration

Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View

Veracyte Non-GAAP EPS of $0.33 beats by $0.16, revenue of $115.86M beats by $6.03M

Reports Q3 revenue $115.9M, consensus $109.81M. "The strong momentum across our testing business continued during the third quarter as we delivered...

Veracyte reports Q3 adjusted EPS 33c, consensus 3c

Consensus $436.14M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's bes...

Veracyte raises FY24 revenue view to $442M-$445M from $432M-$438M

Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript

Veracyte Inc ( ($VCYT) ) has released its Q3 earnings. Here is a breakdown of the information Veracyte Inc presented to its investors. Veracyte Inc...

Veracyte Inc. Reports Strong Q3 2024 Growth

Needham analyst Michael Matson reiterated a Buy rating on Veracyte (VCYT – Research Report) today and set a price target of $44.00. Michael Matson ...

Veracyte's Strong Financial Performance and Growth Potential Lead to Buy Rating and Increased Price Target

SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.

Smaller Cap Biotechs Are In Season: How Are We Doing?

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on PepGen Inc. (PEPG – Research Report), Ligand Pharma ...

Analysts Are Bullish on Top Healthcare Stocks: PepGen Inc. (PEPG), Ligand Pharma (LGND)

In a report released today, Sung Ji Nam from Scotiabank reiterated a Buy rating on Veracyte (VCYT – Research Report), with a price target of $44.00...

Scotiabank Reaffirms Their Buy Rating on Veracyte (VCYT)

Scotiabank raised the firm's price target on Veracyte (VCYT) to $44 from $40 and keeps an Outperform rating on the shares. The company's Q3 revenue...

Comments

Veracyte

Veracyte (VCYT) Opciones

Veracyte (NASDAQ:VCYT) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL